GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (STU:0X40) » Definitions » EV-to-Revenue

AgeX Therapeutics (STU:0X40) EV-to-Revenue : 223.83 (As of Jun. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AgeX Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AgeX Therapeutics's enterprise value is €29.32 Mil. AgeX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.13 Mil. Therefore, AgeX Therapeutics's EV-to-Revenue for today is 223.83.

The historical rank and industry rank for AgeX Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:0X40' s EV-to-Revenue Range Over the Past 10 Years
Min: 17.66   Med: 165.95   Max: 1847.9
Current: 223.79

During the past 7 years, the highest EV-to-Revenue of AgeX Therapeutics was 1847.90. The lowest was 17.66. And the median was 165.95.

STU:0X40's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.69 vs STU:0X40: 223.79

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-22), AgeX Therapeutics's stock price is €13.7163. AgeX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.12. Therefore, AgeX Therapeutics's PS Ratio for today is 113.36.


AgeX Therapeutics EV-to-Revenue Historical Data

The historical data trend for AgeX Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics EV-to-Revenue Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 39.66 173.90 374.52 1,127.06 130.42

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,127.06 1,405.73 1,847.96 376.98 130.42

Competitive Comparison of AgeX Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, AgeX Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's EV-to-Revenue falls into.



AgeX Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

AgeX Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=29.322/0.131
=223.83

AgeX Therapeutics's current Enterprise Value is €29.32 Mil.
AgeX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics  (STU:0X40) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

AgeX Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=13.7163/0.121
=113.36

AgeX Therapeutics's share price for today is €13.7163.
AgeX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (STU:0X40) Business Description

Traded in Other Exchanges
N/A
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

AgeX Therapeutics (STU:0X40) Headlines

No Headlines